



Alaska Medical Assistance DUR Committee Meeting
Friday September 16, 2022
1:00pm
1.800.315.6338, access code 24251#

Please note, as a result of COVID-19 this meeting will be available via teleconference only.

Agenda

- (1) Review of minutes from April
- (2) Review of Agenda
- (3) Comments/Suggestions from Committee members
- (4) Overview of Medicaid Prescription and Cost Trends
- (5) Prospective Drug Utilization Review / Clinical Topic Areas:
 - a. New Prescription Medications (Interim PA List – 6 month review)
 - i. Review of new medications to market since the January meeting
 - b. New Prior Authorizations, Quantity Limits, Edits
 - i. Evryydi, Spinraza
 - c. Review of existing Prior Authorizations, Quantity Limits, Edits
 - i. Soliris, Ultomiris
 - ii. Dupixent
 - iii. Mayzent
 - iv. Opzelura
 - v. Oxbryta
 - vi. Xolair
 - vii. Benlysta
 - viii. Myfembree
 - d. Criteria to be Retired
 - i. PPI
 - ii. Long Acting Beta Agonist
- (6) Opioid Use Trends and ICD-10 Report
- (7) Specialized Medication Counseling
- (8) FDA/DEA Updates
 - a. FDA Drug Safety Communications
- (9) FAERS Reports
- (10) Misc. DUR items
- (11) End of Public Meeting

Pharmaceutical Manufacturers wishing to submit unsolicited clinical information may do so via the form found at the link below:

https://health.alaska.gov/dhcs/Pages/pdl/download_pdl.aspx

Submissions for the September meeting must be received no later than 4pm Alaska local time on September 2, 2022.